Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Follows REGEN-COV Revenue Success With Impressive PD-1 Data

Libtayo Showed Efficacy With Chemo In 1L NSCLC

Executive Summary

Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.

You may also be interested in...



COVID-19 Antibody Cocktail Sweetens Regeneron’s Growth Story

With REGEN-COV in the mix, Regeneron recorded 51% total revenue growth during Q3, including partnership revenue from Roche, but the product’s long-term viability remains in question.

Lilly Pulls COVID-19 Antibody Treatment From EU Review

While Lilly's antibody combination of etesevimab and bamlanivimab is still going strong in the US, the company has lost out to Roche's Ronapreve in the EU.

Lilly Walks Away As Roche Dominates EU’s COVID-19 Antibody Market

Still going strong in the US, Lilly has lost out to Roche’s Ronapreve in the European Union.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel